Critical IllnessMOTIVATE-ICUNCT06288724
MOdifiable facTors to Improve VentilAtion ThErapy in ICU
An observational study of Critical Illness and Invasive Mechanical Ventilation, run by Nat Intensive Care Surveillance - MORU.
Trial summary
ABSTRACT Introduction: Invasively ventilated patients in low and middle-income countries (LMICs) experience significantly higher mortality compared to those in High income countries (HICs). Direct application of HIC strategies to LMICs maybe ineffective due to context-specific challenges. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Critical Illness, Invasive Mechanical Ventilation, ICU Mortality
- How many people
- 625 participants
- Where
- No sites listed yet
- Study dates
- Mar 2024to Sep 2024
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients ≥15 years receiving invasive mechanical ventilation within the ICU
Who may be able to join
- Invasive mechanical ventilatory support initiated anywhere within the study hospital i.e., emergency room, normal ward or in the operating room, or in the ICU at any time during admission.
Who cannot join
- Successful extubations within two calendar days of intubation
- Admissions for end-of-life care and/or ICU palliative support
- Patients transferred from ICUs not participating in the study 24 hours after initiation of MV.
- Refusal or Withdrawal of consent
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Potentially MOdifiable Factors To ImproVe Outcomes of Mechanically Ventilated Patients in ICUs in a Low-income Country: Rationale and Protocol for a Registry-embedded Prospective Observational Study
ABSTRACT Introduction: Invasively ventilated patients in low and middle-income countries (LMICs) experience significantly higher mortality compared to those in High income countries (HICs). Direct application of HIC strategies to LMICs maybe ineffective due to context-specific challenges. This study aims to leverage the Intensive Care Registry of Uganda (ICRU) to identify ICU structural and process-related modifiable factors that impact patient outcomes in a low income country.
Methods: The MOTIVATE-ICU is a prospective multicentre observational study in invasively ventilated patients. It involves a registry-embedded component examining patient- and process-related factors and a cross-sectional survey on ICU organizational structures. Inclusion criteria encompass patients aged ≥ 15 years undergoing IMV in Ugandan ICUs. Primary outcomes are ICU mortality, ICU length of stay (LOS), and duration of ventilation. Secondary outcomes include ventilator-associated complications, non-pulmonary organ support. tTracheostomy outcomes will be explored in a pre-planned substudy. Factors potentially associated with outcomes will be categorized into two groups; non-modifiable factors and potentially modifiable. Non-modifiable factors will include patient-related factors like age, comorbidities and illness severity; potentially modifiable factors include processes of care (e.g. sedation levels) and ICU organizational structure (e.g. staffing patterns). Multilevel multivariable logistic regression will be utilized to study associations, with both patient and ICU level fixed effects considered.
Ethics and Dissemination: Given its observational nature, this study seeks a waiver for patient individual informed consent. Data anonymization ensures patient privacy. Following the principles of the Declaration of Helsinki, relevant ethical approvals will be acquired. Study findings will be disseminated through conferences and peer-reviewed journals.
Read the detailed description
Introduction:
In low and middle-income countries (LMICs), up to two-thirds of ICU admissions necessitate invasive mechanical ventilation (IMV), compared to half of ICU admissions globally1-3. Though IMV is a life saving organ support technique, it's also linked to complications like ventilator associated lung injury and requires complex processes of care4. Despite being younger, ventilated patients in LMICs have 2-4 times higher mortality than high-income countries (HICs)5-8. Patients with acute respiratory distress syndrome (ARDS) in LMICs face an even greater risk, 70% higher than in HICs9.
While HICs have ample data on modifiable factors and improvement strategies that curtail ICU complications, LMICs may face preventable complications associated with IMV1,10-13. Complications like ventilator-induced lung injury and related pneumonia lead not only to excess deaths but also longer ICU stays and escalating costs14. Unfortunately, data on determinants of poor outcome among ventilated patients in LMICs remains scarce 12,15-17. Directly applying HIC evidence based management strategies to LMICs isn't always effective, as seen in several African trials 18,19. LMICs grapple with challenges like understaffing, limited training, insufficient infrastructure, and different patient characteristics and comorbidities, all potentially compromising the quality of ICU care15,16,20,21.
Recently, the use of critical care registries for data collection, including patient care, indicators, and outcomes, has expanded in both HICs and LMICs22-24. This streamlines research and offers cost benefits. Uganda has launched the Intensive Care Registry of Uganda (ICRU) for quality improvement and research infrastructure. This registry-embedded study aims to identify modifiable factors impacting outcomes for mechanically ventilated patients in LMICs leveraging ICRU's data pipeline. We hypothesize that specific patient-level and organizational factors can be identified that contribute to the ICU mortality of ventilated patients in Uganda.
Methods and Analysis:
Study design:
The 'Potentially MOdifiable factors To ImproVe outcomes of mechanically Ventilated patients in ICUs in a Low-income Country' (MOTIVATE-ICU) study is a prospective multicentre registry-embedded observational study with two main components. The first will be a prospective observational multicenter registry-embedded study aimed at assessing patient-related and process-related factors. The second component will be a cross-sectional survey to assess the organizational structure of the ICUs included. This study protocol was registered at Clinicaltrials.gov (registration number: NCTXXXXXXX). The results of the study will be reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement25.
Study setting:
ICUs will be defined as geographically designated area/unit within a hospital that routinely provides invasive mechanical ventilation therapy with continuous vital sign monitoring [electrocardiographic (ECG) monitoring, heart/pulse rate, non-invasive blood pressure (NIBP), peripheral oxygen saturation (SpO2)] and designated nursing care for each bed in the unit i.e at least three patients per week for at least 24 hours. A descriptive study conducted in Uganda assessing the ICU capacity before the Corona virus induced disease 2019 (COVID-19) revealed that at the time, there were 14 ICUs with 12 being functional20. However, post-COVID-19, anecdotal evidence shows nearly a doubling of the ICU capacity with nearly 25 functional ICUs to-date. All ICUs currently functional in Uganda will be eligible to participate (eTable 1).
Participants:
Patients aged ≥ 15 years admitted to study ICUs during the study period and receiving invasive mechanical ventilation will be eligible for recruitment. Exclusion criteria include successful extubations within 24 hours of intubation, admissions for end-of-life care and/or ICU palliative support as well as patients transferred from ICUs not participating in the study 24 hours after initiation of MV.
Outcomes:
Primary outcomes The primary outcomes will be ICU mortality, ICU length of stay (LOS) and duration of mechanical ventilation. Outcome definitions are detailed in Table 1.
Secondary outcomes These will include duration of non-pulmonary organ support, ICU-free days, ventilator-free days at day 28, ventilator-associated pneumonia (VAP), tracheobronchitis, non-infectious pulmonary complication (clinician suspicion or radiological diagnosis of pleural effusion, atelectasis or pneumothorax), readmission, unplanned extubations. Tracheostomy related outcomes will be explored as part of a preplanned substudy, including tracheostomy timing, decannulation rate, decannulation failure and complications such as stoma infection, major bleeding, tube dislodgement and malfunction.
Associated factors (Table 2):
Factors potentially associated with outcomes among mechanically ventilated patients will be analyzed as 'non-modifiable' factors and 'potentially modifiable' factors. Non-modifiable factors include patient-related factors such as age, illness severity at initiation of mechanical ventilation, comorbidities, medical vs surgical admission, and indication for IMV (Table 2). Potentially modifiable factors will subcategorized into care process-related factors such as Richmond Agitation Sedation Scale (RASS) targets, initial ventilator settings on day 0, use of daily spontaneous awakening and spontaneous breathing trials, use of stress ulcer and deep vein thrombosis (DVT) prophylaxis. The second subcategory will be ICU organizational structure such ICU staffing, staff-patient ratios, empowerment of non-physician staff, multidisciplinary team rounds and use of protocols and checklists (Details on associated factors in supplementary material Table 2).
Data collection:
The following procedures will be performed to ensure the quality of the data collection Patient-level data will be entered directly via laptop or tablet through the cloud-based ICU registry platform (PROTECT cloud-based platform) of the ICRU currently in use (Figure 1).
Patient level variables of interest including age, sex, diagnostic categories, functional capacity before hospital admission (Clinical Frailty Score), the Charlson Comorbidity Index, the use of IMV on Day 1, modified Sequential Organ Function Assessment (mSOFA) and Tropical Intensive Care Score (e-TropICS) will be scored. ICU level variables of interest included ICU type (medical-surgical vs. specialty), presence of training programs in critical care, ICU admission volumes in the preceding year, staffing patterns, organizational and process characteristics; a full list of potential covariates is detailed in Table 2.
We shall extract prospectively collected data from the ICRU platform, which has both core data variables collected at admission and daily variables collected during the ICU stay.
A complete list of variables is detailed in Supplementary materials. The platform uses a common data model and provides real-time data on casemix, management features and outcomes. MOTIVATE-ICU study variables were incorporated into the PROTECT platform in order to design a registry embedded study (Figure 1). The following site-level procedures will be followed:
To ensure standardization of the study procedures, each site shall have a site lead and dedicated data entrant(s) responsible for data collection during use of the ICU registry platform. Prior to the beginning of recruitment, each site lead and data entrant(s) will receive training.
Each site will have a site lead responsible for weekly validation of patient episodes in terms of completion and data quality.
Each site will have IT support as well as participate in monthly meetings as a means of dispelling doubts and solving potential challenges related to data entry.
For each site, data on hospital and ICU organizational and care process characteristics will be collected through an interviewer-administered questionnaire from the ICU director and/or the in-charge nurse.
Follow-up:
Given the potential burden of data collection involved, the patient recruitment period in each participating ICU will be a minimum of three months up to a maximum of 6 months, with a 28-day maximum follow-up period for each patient recruited. The follow up period for individual patients will end at ICU discharge.
Procedures to ensure data quality
Sample size:
We aim to include all consecutive patients admitted to participating ICUs in order to reduce potential selection bias and minimise temporal variation of care processes. Based on aggregated data (published and unpublished) from LMICs including Uganda's ICU cohorts2,10,12,26-31 the lowest measured mortality among patients receiving invasive mechanical ventilation was approximately 40%. A total of 250 events (deaths) would allow us to evaluate at least 25 associated variables in multivariable models. We will therefore enroll at least 625 patients receiving invasive mechanical ventilation that fulfill the eligibility criteria.
Handling of missing data:
During the study period, all data pertinent to the study objectives will be mandated for all study ICUs. The study platform will flag missing data to the data collector in case of incompleteness. Each site lead will ensure validation of patients entered and completeness of the data weekly to ensure no missing data. This is being a prospective registry-embedded study, we expect a low percentage of missing data pertinent to the primary objectives of the study.
Statistical analysis:
We will describe ICU and patient characteristics using standard descriptive statistics and reported continuous variables as mean ± standard deviation or median (25%-75% interquartile range, IQR), as appropriate. We will test the univariate association between eligible variables and outcomes using analysis of variance, Kruskal-Wallis, Student t test, Mann-Whitney test, chi-square test, and Fisher exact test, as appropriate.
Using multilevel multivariable logistic regression models, we shall investigate the association between organizational factors and the primary outcome adjusting for patients' characteristics. A two-level model will be fit with patient-level fixed effects at the first level and ICU-level fixed effects at the second level, as well as an ICU-specific random effect. We will pre-specify several models to represent the patients and the unit organization dimensions. We shall then insert variables into the models if they are associated with outcome with a P value of <0.20 on univariate analysis. We shall not consider variables used for e-TropICS score computation. We shall apply several variables into the final model regardless of their statistical significance due to their clinical significance, including the presence of 24/7 intensivist, regular multidisciplinary rounds and nurse/bed ratios in the final model. In addition, we shall perform subgroup analyses stratifying patients according to the type of admission (medical vs. surgical) and the e-TropICS tertiles. We shall use the Akaike information criterion, the likelihood ratios and the model residuals to choose among the alternative models. Two-tailed P-values <0.05 were considered statistically significant. All statistical analyses will be conducted in R (http://www.r-project.org) and SPSS 21 (IBM Corp., Armonk, NY). A detailed statistical analysis plan will be made available online before completion of the study and locking of the database.
Ethics and dissemination:
Ethical approval and consent to participate This study will be conducted according to the principles of the Declaration of Helsinki (revision Fortaleza, Brazil, October 2013). Approval to carry out this study will be sought from the relevant ethical review and scientific review committees and from hospital administrations.
We shall obtain deferred consent within 72 hours of recruitment into the study from the legal representative since most ICU admissions are emergency admissions and informed consent during the initial 48 hours of admission may not be possible. In addition, without exception, patients admitted to ICU for ventilator support are unable to give informed consent. Persons who may take the role of legal representative in accordance with the Medical Treatment Agreement Act (WGBO) are: a predefined representative, husband or wife, registered partner or other life partner, a parent or child, brother or sister, and incidentally a curator appointed by a judge. For patients with no legal representative and are unable to give informed consent during in-hospital stay, we shall obtain a waiver of consent. The experience of ICU patients enrolled under deferred consent is mainly positive, as shown in the NICE-SUGAR trial, in which participants were included using deferred consent32. A majority of the patients were happy with the decision made by the representative (93%) and would have granted consent if asked (96%)33.
Oral consent from each of the ICU directors and/or in-charge nurse will be sought to conduct the interviewer-administered survey.
Dissemination:
The study results will be submitted for publication regardless of the results after completion and analysis. We shall make the study findings widely available including dissemination through conferences and peer-reviewed journals.
Data sharing:
The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data. ICRU is part of a larger network which has appointed a Data Access Committee (DAC). Curated data may be shared with third parties for research purposes following written approval from the DAC.
Discussion and study status:
The MOTIVATE-ICU registry-embedded study aims to identify potentially modifiable factors associated with outcomes among invasively ventilated patients in a low income country.
According to the Donabedian model improving the quality of healthcare and improving outcomes of interest, rests on three components; the structure, care processes and outcomes.34 Various studies from HICs on ICU organization structure, care-bundles and protocols have shown significant impact in reduction of mortality, duration of ventilation and ICU length of stay; albeit with some inconsistencies in some aspects.6,11,35-37 Based on what we currently know from the ORCHESTRA study done in Brazil, an upper middle income country (UMIC), organizational factors including protocol implementation are the key targets to improve ICU outcomes and efficiency38,39. There has been considerable data describing the physical structural set-up and staffing of ICUs in LMICs20,26,40,41, but limited data is available on organizational features and care-processes, and their impact on outcomes in lower income settings like Uganda.
Direct implementation of evidence-based care processes from higher income settings may not necessarily yield similar results when implemented in resource-poor settings. For example, two African studies that implemented fluid therapy as per protocols used in HICs revealed more harm than benefit in both critically ill adults and paediatric populations18,19. For other processes, implementation in LMICs has improved consistently but outcomes remain lagging when compared to HICs, probably affected by a multitude of factors. For instance, use of protective mechanical ventilation in patients without ARDS was shown to be comparable between MICs and HICS during first days of ventilation, but with a large difference in ICU mortality14. The same was seen for ventilation in ARDS patients, albeit with a small difference in protective ventilation implementation1,6.
One of the key potential interventions likely to show impact in low-resource settings compared to HICs is tracheostomy placement and timing. Tracheostomy timing, while improving ICU length of stay and duration of mechanical ventilation has not had an impact on mortality in HICs42-44, but may have a significant impact in a setting with limited resources. A preplanned substudy of MOTIVATE-ICU will explore timing, complications and outcomes in patients undergoing tracheostomy in a low income country like Uganda, complementing data from LMICs from other African countries45,46.
The strengths of the current study are its prospective design, registry-embedded nature, and multicenter inclusion. There are several potential limitations of this study. For example, while efforts are made to ensure data quality and reduce missing data, the reliance on electronic data collection and the prospective nature of the study may still encounter challenges with data completeness and accuracy across multiple centers. The study's findings, especially those related to organizational structure and process-related factors, may be specific to the context of low-income countries and thus may not be generalizable to settings with different healthcare systems, resources, and ICU capabilities. The cross-sectional survey assessing the organizational structure of ICUs, rely on self-reported data, which can introduce biases and inaccuracies.
Acknowledgements:
We thank all the site leads and data entrants of each site at each of the participating hospitals as well as Critical Care Asia Africa network for the support and involvement in the success of this study.
Funding:
The study will be supported by the Wellcome award, Collaboration for Research, Implementation and Training in Critical Care in Asia and Africa (Grant number: 224048/Z/21/Z).
- Conditions
- Critical Illness, Invasive Mechanical Ventilation, ICU Mortality, Developing Countries, Risk Factors
- Medical subject headings
- Critical Illness
What is being measured
The primary outcome is the main question the study is designed to answer.
ICU mortality
Death at ICU discharge, or at 28 days after ICU admission, whichever occurs first.
Measured: 28 days
ICU Length of Stay
Number of days patients spend in the ICU. Measured per episode of ICU care. Calculated using the interval (measured in hours) between the date and time of ICU admission and the date and time of ICU discharge. Rounded to the nearest 1 decimal place.
Measured: 28 days
Duration of mechanical ventilation
The time between endotracheal intubation and successful extubation (in case of intermittent mechanical ventilation via a tracheostomy, every day a patient needs ventilation counts as one extra day, irrespective of the duration of ventilation on that specific day). In case of non-invasive ventilation, the duration will be assessed separated from the assessment of invasive ventilation.
Measured: 28 days
Secondary outcomes (9)
Duration of non-pulmonary organ support
Time between initiation of vasopressor/inotropic support or renal replacement therapy to the time of discontinuation for at least 24 hours. Individual components of the composite outcome will be reported.
Measured: 28 days
ICU-Free days
Number of in-hospital days from ICU discharge to 28 days. If the patient dies after ICU discharge and before 28 days this will count as 0
Measured: 28 days
Ventilator-free days
The number of ventilator-free days at 28 days (VFD-28) will be determined by subtracting the total duration of mechanical ventilation from 30 days. If a patient passed away before reaching the 28-day mark, their VFD-28 will be recorded as having zero VFD-28
Measured: 28 days
Ventilator-associated Pneumonia
Presence of fever OR Altered leukocyte count PLUS New onset of purulent endotracheal secretions OR change in sputum WITH new and progressive or persistent infiltrate or consolidation or cavitation48 For those without radiological diagnosis, we shall consider clinically suspected VAP.
Measured: 28 days
Tracheobronchitis
Presence of fever OR altered leukocyte count (<4 or >12 x 103) PLUS New onset of purulent endotracheal secretions OR change in sputum
Measured: 28 days
Non-infectious Pulmonary complication
Clinician suspicion or radiological diagnosis of pleural effusion, atelectasis or pneumothorax
Measured: 28 days
Readmission
Unplanned ICU admission within 48 hours after ICU discharge
Measured: 28 days
Unplanned extubations
Inadvertent/accidental extubations requiring reintubation
Measured: 28 days
Tracheostomy related outcomes
The following outcomes will be included:
Timing of tracheostomy in terms of number of days after intubation; decannulation rate, i.e. the proportion of patients undergoing successful decannulation during ICU stay decannulation failure (defined as the need to recannulate for any reason between decannulation and hospital discharge); Tracheostomy-related complications: stoma infection, major bleeding, tube dislodgement, and malfunction defined as air leaks
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Mar 2024
- Study startMar 2024 (estimated)
- Primary completionSep 2024 (estimated)
- Study completionSep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (51)Papers the sponsor has linked to this study.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 625 participants (estimated)
- Target duration
- 28 Days
Sponsor and investigators
- Lead sponsor
- Nat Intensive Care Surveillance - MORU
- Sponsor type
- University, hospital or other
- Collaborators
- D'Or Institute for Research and Education, University of Oxford, Wellcome Trust, Makerere University
- Responsible party
- Principal investigator, Cornelius Sendagire, Nat Intensive Care Surveillance - MORU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06288724
- Sponsor's protocol ID
- NatIntensive
- Acronym
- MOTIVATE-ICU
- Status last verified
- Feb 2024
- First submitted
- 24 Feb 2024
- Last updated
- 1 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Laffey JG, Bellani G, Pham T, Fan E, Madotto F, Bajwa EK, Brochard L, Clarkson K, Esteban A, Gattinoni L, van Haren F, Heunks LM, Kurahashi K, Laake JH, Larsson A, McAuley DF, McNamee L, Nin N, Qiu H, Ranieri M, Rubenfeld GD, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators and the ESICM Trials Group. Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. Intensive Care Med. 2016 Dec;42(12):1865-1876. doi: 10.1007/s00134-016-4571-5. Epub 2016 Oct 18.
PubMed 27757516Prin M, Itaye T, Clark S, Fernando RJ, Namboya F, Pollach G, Mkandawire N, Sobol J. Critical Care in a Tertiary Hospital in Malawi. World J Surg. 2016 Nov;40(11):2635-2642. doi: 10.1007/s00268-016-3578-y.
PubMed 27230398Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010 Oct 16;376(9749):1339-46. doi: 10.1016/S0140-6736(10)60446-1. Epub 2010 Oct 11.
PubMed 20934212Goligher EC, Ferguson ND, Brochard LJ. Clinical challenges in mechanical ventilation. Lancet. 2016 Apr 30;387(10030):1856-66. doi: 10.1016/S0140-6736(16)30176-3. Epub 2016 Apr 28.
PubMed 27203509Inglis R, Ayebale E, Schultz MJ. Optimizing respiratory management in resource-limited settings. Curr Opin Crit Care. 2019 Feb;25(1):45-53. doi: 10.1097/MCC.0000000000000568.
PubMed 30531535Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291.
PubMed 26903337Neto AS, Barbas CSV, Simonis FD, Artigas-Raventos A, Canet J, Determann RM, Anstey J, Hedenstierna G, Hemmes SNT, Hermans G, Hiesmayr M, Hollmann MW, Jaber S, Martin-Loeches I, Mills GH, Pearse RM, Putensen C, Schmid W, Severgnini P, Smith R, Treschan TA, Tschernko EM, Melo MFV, Wrigge H, de Abreu MG, Pelosi P, Schultz MJ; PRoVENT; PROVE Network investigators. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med. 2016 Nov;4(11):882-893. doi: 10.1016/S2213-2600(16)30305-8. Epub 2016 Oct 4.
PubMed 27717861Khatib KI, Dixit SB, Joshi MM. Factors determining outcomes in adult patient undergoing mechanical ventilation: A "real-world" retrospective study in an Indian Intensive Care Unit. Int J Crit Illn Inj Sci. 2018 Jan-Mar;8(1):9-16. doi: 10.4103/IJCIIS.IJCIIS_41_17.
PubMed 29619334Laffey JG, Madotto F, Bellani G, Pham T, Fan E, Brochard L, Amin P, Arabi Y, Bajwa EK, Bruhn A, Cerny V, Clarkson K, Heunks L, Kurahashi K, Laake JH, Lorente JA, McNamee L, Nin N, Palo JE, Piquilloud L, Qiu H, Jimenez JIS, Esteban A, McAuley DF, van Haren F, Ranieri M, Rubenfeld G, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study. Lancet Respir Med. 2017 Aug;5(8):627-638. doi: 10.1016/S2213-2600(17)30213-8. Epub 2017 Jun 15.
PubMed 28624388African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet. 2021 May 22;397(10288):1885-1894. doi: 10.1016/S0140-6736(21)00441-4.
PubMed 34022988Simonis FD, Barbas CSV, Artigas-Raventos A, Canet J, Determann RM, Anstey J, Hedenstierna G, Hemmes SNT, Hermans G, Hiesmayr M, Hollmann MW, Jaber S, Martin-Loeches I, Mills GH, Pearse RM, Putensen C, Schmid W, Severgnini P, Smith R, Treschan TA, Tschernko EM, Vidal Melo MF, Wrigge H, de Abreu MG, Pelosi P, Schultz MJ, Neto AS; PRoVENT investigators; PROVE Network investigators. Potentially modifiable respiratory variables contributing to outcome in ICU patients without ARDS: a secondary analysis of PRoVENT. Ann Intensive Care. 2018 Mar 21;8(1):39. doi: 10.1186/s13613-018-0385-7.
PubMed 29564726Karthikeyan B, Kadhiravan T, Deepanjali S, Swaminathan RP. Case-Mix, Care Processes, and Outcomes in Medically-Ill Patients Receiving Mechanical Ventilation in a Low-Resource Setting from Southern India: A Prospective Clinical Case Series. PLoS One. 2015 Aug 11;10(8):e0135336. doi: 10.1371/journal.pone.0135336. eCollection 2015.
PubMed 26262995Dijkema LM, Dieperink W, van Meurs M, Zijlstra JG. Preventable mortality evaluation in the ICU. Crit Care. 2012 Dec 12;16(2):309. doi: 10.1186/cc11212.
PubMed 22546292Pisani L, Algera AG, Neto AS, Azevedo L, Pham T, Paulus F, de Abreu MG, Pelosi P, Dondorp AM, Bellani G, Laffey JG, Schultz MJ; ERICC study investigators; LUNG SAFE study investigators; PRoVENT study investigators; PRoVENT-iMiC study investigators. Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies. Lancet Glob Health. 2022 Feb;10(2):e227-e235. doi: 10.1016/S2214-109X(21)00485-X. Epub 2021 Dec 13.
PubMed 34914899Vukoja M, Riviello E, Gavrilovic S, Adhikari NK, Kashyap R, Bhagwanjee S, Gajic O, Kilickaya O; CERTAIN Investigators. A survey on critical care resources and practices in low- and middle-income countries. Glob Heart. 2014 Sep;9(3):337-42.e1-5. doi: 10.1016/j.gheart.2014.08.002. Epub 2014 Oct 31.
PubMed 25667185
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Potentially MOdifiable Factors To ImproVe Outcomes of Mechanically Ventilated Patients in ICUs in a Low-income Country: Rationale and Protocol for a Registry-embedded Prospective Observational Study
- ClinicalTrials.gov ID
- NCT06288724
- Acronym / sponsor ID
- MOTIVATE-ICU / NatIntensive
- Conditions
- Critical Illness, Invasive Mechanical Ventilation, ICU Mortality, Developing Countries, Risk Factors
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 625 participants (estimated)
- Lead sponsor
- Nat Intensive Care Surveillance - MORUUniversity, hospital or other
- Collaborators
- D'Or Institute for Research and Education, University of Oxford, Wellcome Trust, Makerere University
- Study start
- Mar 2024 (estimated)
- Primary completion
- Sep 2024 (estimated)
- Study completion
- Sep 2024 (estimated)
- First posted
- 1 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ABSTRACT Introduction: Invasively ventilated patients in low and middle-income countries (LMICs) experience significantly higher mortality compared to those in High income countries (HICs). Direct application of HIC strategies to LMICs maybe ineffective due to context-specific challenges. This study aims to leverage the Intensive Care Registry of Uganda (ICRU) to identify ICU structural and process-related modifiable factors that impact patient outcomes in a low income country.
Methods: The MOTIVATE-ICU is a prospective multicentre observational study in invasively ventilated patients. It involves a registry-embedded component examining patient- and process-related factors and a cross-sectional survey on ICU organizational structures. Inclusion criteria encompass patients aged ≥ 15 years undergoing IMV in Ugandan ICUs. Primary outcomes are ICU mortality, ICU length of stay (LOS), and duration of ventilation. Secondary outcomes include ventilator-associated complications, non-pulmonary organ support. tTracheostomy outcomes will be explored in a pre-planned substudy. Factors potentially associated with outcomes will be categorized into two groups; non-modifiable factors and potentially modifiable. Non-modifiable factors will include patient-related factors like age, comorbidities and illness severity; potentially modifiable factors include processes of care (e.g. sedation levels) and ICU organizational structure (e.g. staffing patterns). Multilevel multivariable logistic regression will be utilized to study associations, with both patient and ICU level fixed effects considered.
Ethics and Dissemination: Given its observational nature, this study seeks a waiver for patient individual informed consent. Data anonymization ensures patient privacy. Following the principles of the Declaration of Helsinki, relevant ethical approvals will be acquired. Study findings will be disseminated through conferences and peer-reviewed journals.
Detailed description
Introduction:
In low and middle-income countries (LMICs), up to two-thirds of ICU admissions necessitate invasive mechanical ventilation (IMV), compared to half of ICU admissions globally1-3. Though IMV is a life saving organ support technique, it's also linked to complications like ventilator associated lung injury and requires complex processes of care4. Despite being younger, ventilated patients in LMICs have 2-4 times higher mortality than high-income countries (HICs)5-8. Patients with acute respiratory distress syndrome (ARDS) in LMICs face an even greater risk, 70% higher than in HICs9.
While HICs have ample data on modifiable factors and improvement strategies that curtail ICU complications, LMICs may face preventable complications associated with IMV1,10-13. Complications like ventilator-induced lung injury and related pneumonia lead not only to excess deaths but also longer ICU stays and escalating costs14. Unfortunately, data on determinants of poor outcome among ventilated patients in LMICs remains scarce 12,15-17. Directly applying HIC evidence based management strategies to LMICs isn't always effective, as seen in several African trials 18,19. LMICs grapple with challenges like understaffing, limited training, insufficient infrastructure, and different patient characteristics and comorbidities, all potentially compromising the quality of ICU care15,16,20,21.
Recently, the use of critical care registries for data collection, including patient care, indicators, and outcomes, has expanded in both HICs and LMICs22-24. This streamlines research and offers cost benefits. Uganda has launched the Intensive Care Registry of Uganda (ICRU) for quality improvement and research infrastructure. This registry-embedded study aims to identify modifiable factors impacting outcomes for mechanically ventilated patients in LMICs leveraging ICRU's data pipeline. We hypothesize that specific patient-level and organizational factors can be identified that contribute to the ICU mortality of ventilated patients in Uganda.
Methods and Analysis:
Study design:
The 'Potentially MOdifiable factors To ImproVe outcomes of mechanically Ventilated patients in ICUs in a Low-income Country' (MOTIVATE-ICU) study is a prospective multicentre registry-embedded observational study with two main components. The first will be a prospective observational multicenter registry-embedded study aimed at assessing patient-related and process-related factors. The second component will be a cross-sectional survey to assess the organizational structure of the ICUs included. This study protocol was registered at Clinicaltrials.gov (registration number: NCTXXXXXXX). The results of the study will be reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement25.
Study setting:
ICUs will be defined as geographically designated area/unit within a hospital that routinely provides invasive mechanical ventilation therapy with continuous vital sign monitoring [electrocardiographic (ECG) monitoring, heart/pulse rate, non-invasive blood pressure (NIBP), peripheral oxygen saturation (SpO2)] and designated nursing care for each bed in the unit i.e at least three patients per week for at least 24 hours. A descriptive study conducted in Uganda assessing the ICU capacity before the Corona virus induced disease 2019 (COVID-19) revealed that at the time, there were 14 ICUs with 12 being functional20. However, post-COVID-19, anecdotal evidence shows nearly a doubling of the ICU capacity with nearly 25 functional ICUs to-date. All ICUs currently functional in Uganda will be eligible to participate (eTable 1).
Participants:
Patients aged ≥ 15 years admitted to study ICUs during the study period and receiving invasive mechanical ventilation will be eligible for recruitment. Exclusion criteria include successful extubations within 24 hours of intubation, admissions for end-of-life care and/or ICU palliative support as well as patients transferred from ICUs not participating in the study 24 hours after initiation of MV.
Outcomes:
Primary outcomes The primary outcomes will be ICU mortality, ICU length of stay (LOS) and duration of mechanical ventilation. Outcome definitions are detailed in Table 1.
Secondary outcomes These will include duration of non-pulmonary organ support, ICU-free days, ventilator-free days at day 28, ventilator-associated pneumonia (VAP), tracheobronchitis, non-infectious pulmonary complication (clinician suspicion or radiological diagnosis of pleural effusion, atelectasis or pneumothorax), readmission, unplanned extubations. Tracheostomy related outcomes will be explored as part of a preplanned substudy, including tracheostomy timing, decannulation rate, decannulation failure and complications such as stoma infection, major bleeding, tube dislodgement and malfunction.
Associated factors (Table 2):
Factors potentially associated with outcomes among mechanically ventilated patients will be analyzed as 'non-modifiable' factors and 'potentially modifiable' factors. Non-modifiable factors include patient-related factors such as age, illness severity at initiation of mechanical ventilation, comorbidities, medical vs surgical admission, and indication for IMV (Table 2). Potentially modifiable factors will subcategorized into care process-related factors such as Richmond Agitation Sedation Scale (RASS) targets, initial ventilator settings on day 0, use of daily spontaneous awakening and spontaneous breathing trials, use of stress ulcer and deep vein thrombosis (DVT) prophylaxis. The second subcategory will be ICU organizational structure such ICU staffing, staff-patient ratios, empowerment of non-physician staff, multidisciplinary team rounds and use of protocols and checklists (Details on associated factors in supplementary material Table 2).
Data collection:
The following procedures will be performed to ensure the quality of the data collection Patient-level data will be entered directly via laptop or tablet through the cloud-based ICU registry platform (PROTECT cloud-based platform) of the ICRU currently in use (Figure 1).
Patient level variables of interest including age, sex, diagnostic categories, functional capacity before hospital admission (Clinical Frailty Score), the Charlson Comorbidity Index, the use of IMV on Day 1, modified Sequential Organ Function Assessment (mSOFA) and Tropical Intensive Care Score (e-TropICS) will be scored. ICU level variables of interest included ICU type (medical-surgical vs. specialty), presence of training programs in critical care, ICU admission volumes in the preceding year, staffing patterns, organizational and process characteristics; a full list of potential covariates is detailed in Table 2.
We shall extract prospectively collected data from the ICRU platform, which has both core data variables collected at admission and daily variables collected during the ICU stay.
A complete list of variables is detailed in Supplementary materials. The platform uses a common data model and provides real-time data on casemix, management features and outcomes. MOTIVATE-ICU study variables were incorporated into the PROTECT platform in order to design a registry embedded study (Figure 1). The following site-level procedures will be followed:
To ensure standardization of the study procedures, each site shall have a site lead and dedicated data entrant(s) responsible for data collection during use of the ICU registry platform. Prior to the beginning of recruitment, each site lead and data entrant(s) will receive training.
Each site will have a site lead responsible for weekly validation of patient episodes in terms of completion and data quality.
Each site will have IT support as well as participate in monthly meetings as a means of dispelling doubts and solving potential challenges related to data entry.
For each site, data on hospital and ICU organizational and care process characteristics will be collected through an interviewer-administered questionnaire from the ICU director and/or the in-charge nurse.
Follow-up:
Given the potential burden of data collection involved, the patient recruitment period in each participating ICU will be a minimum of three months up to a maximum of 6 months, with a 28-day maximum follow-up period for each patient recruited. The follow up period for individual patients will end at ICU discharge.
Procedures to ensure data quality
Sample size:
We aim to include all consecutive patients admitted to participating ICUs in order to reduce potential selection bias and minimise temporal variation of care processes. Based on aggregated data (published and unpublished) from LMICs including Uganda's ICU cohorts2,10,12,26-31 the lowest measured mortality among patients receiving invasive mechanical ventilation was approximately 40%. A total of 250 events (deaths) would allow us to evaluate at least 25 associated variables in multivariable models. We will therefore enroll at least 625 patients receiving invasive mechanical ventilation that fulfill the eligibility criteria.
Handling of missing data:
During the study period, all data pertinent to the study objectives will be mandated for all study ICUs. The study platform will flag missing data to the data collector in case of incompleteness. Each site lead will ensure validation of patients entered and completeness of the data weekly to ensure no missing data. This is being a prospective registry-embedded study, we expect a low percentage of missing data pertinent to the primary objectives of the study.
Statistical analysis:
We will describe ICU and patient characteristics using standard descriptive statistics and reported continuous variables as mean ± standard deviation or median (25%-75% interquartile range, IQR), as appropriate. We will test the univariate association between eligible variables and outcomes using analysis of variance, Kruskal-Wallis, Student t test, Mann-Whitney test, chi-square test, and Fisher exact test, as appropriate.
Using multilevel multivariable logistic regression models, we shall investigate the association between organizational factors and the primary outcome adjusting for patients' characteristics. A two-level model will be fit with patient-level fixed effects at the first level and ICU-level fixed effects at the second level, as well as an ICU-specific random effect. We will pre-specify several models to represent the patients and the unit organization dimensions. We shall then insert variables into the models if they are associated with outcome with a P value of <0.20 on univariate analysis. We shall not consider variables used for e-TropICS score computation. We shall apply several variables into the final model regardless of their statistical significance due to their clinical significance, including the presence of 24/7 intensivist, regular multidisciplinary rounds and nurse/bed ratios in the final model. In addition, we shall perform subgroup analyses stratifying patients according to the type of admission (medical vs. surgical) and the e-TropICS tertiles. We shall use the Akaike information criterion, the likelihood ratios and the model residuals to choose among the alternative models. Two-tailed P-values <0.05 were considered statistically significant. All statistical analyses will be conducted in R (http://www.r-project.org) and SPSS 21 (IBM Corp., Armonk, NY). A detailed statistical analysis plan will be made available online before completion of the study and locking of the database.
Ethics and dissemination:
Ethical approval and consent to participate This study will be conducted according to the principles of the Declaration of Helsinki (revision Fortaleza, Brazil, October 2013). Approval to carry out this study will be sought from the relevant ethical review and scientific review committees and from hospital administrations.
We shall obtain deferred consent within 72 hours of recruitment into the study from the legal representative since most ICU admissions are emergency admissions and informed consent during the initial 48 hours of admission may not be possible. In addition, without exception, patients admitted to ICU for ventilator support are unable to give informed consent. Persons who may take the role of legal representative in accordance with the Medical Treatment Agreement Act (WGBO) are: a predefined representative, husband or wife, registered partner or other life partner, a parent or child, brother or sister, and incidentally a curator appointed by a judge. For patients with no legal representative and are unable to give informed consent during in-hospital stay, we shall obtain a waiver of consent. The experience of ICU patients enrolled under deferred consent is mainly positive, as shown in the NICE-SUGAR trial, in which participants were included using deferred consent32. A majority of the patients were happy with the decision made by the representative (93%) and would have granted consent if asked (96%)33.
Oral consent from each of the ICU directors and/or in-charge nurse will be sought to conduct the interviewer-administered survey.
Dissemination:
The study results will be submitted for publication regardless of the results after completion and analysis. We shall make the study findings widely available including dissemination through conferences and peer-reviewed journals.
Data sharing:
The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data. ICRU is part of a larger network which has appointed a Data Access Committee (DAC). Curated data may be shared with third parties for research purposes following written approval from the DAC.
Discussion and study status:
The MOTIVATE-ICU registry-embedded study aims to identify potentially modifiable factors associated with outcomes among invasively ventilated patients in a low income country.
According to the Donabedian model improving the quality of healthcare and improving outcomes of interest, rests on three components; the structure, care processes and outcomes.34 Various studies from HICs on ICU organization structure, care-bundles and protocols have shown significant impact in reduction of mortality, duration of ventilation and ICU length of stay; albeit with some inconsistencies in some aspects.6,11,35-37 Based on what we currently know from the ORCHESTRA study done in Brazil, an upper middle income country (UMIC), organizational factors including protocol implementation are the key targets to improve ICU outcomes and efficiency38,39. There has been considerable data describing the physical structural set-up and staffing of ICUs in LMICs20,26,40,41, but limited data is available on organizational features and care-processes, and their impact on outcomes in lower income settings like Uganda.
Direct implementation of evidence-based care processes from higher income settings may not necessarily yield similar results when implemented in resource-poor settings. For example, two African studies that implemented fluid therapy as per protocols used in HICs revealed more harm than benefit in both critically ill adults and paediatric populations18,19. For other processes, implementation in LMICs has improved consistently but outcomes remain lagging when compared to HICs, probably affected by a multitude of factors. For instance, use of protective mechanical ventilation in patients without ARDS was shown to be comparable between MICs and HICS during first days of ventilation, but with a large difference in ICU mortality14. The same was seen for ventilation in ARDS patients, albeit with a small difference in protective ventilation implementation1,6.
One of the key potential interventions likely to show impact in low-resource settings compared to HICs is tracheostomy placement and timing. Tracheostomy timing, while improving ICU length of stay and duration of mechanical ventilation has not had an impact on mortality in HICs42-44, but may have a significant impact in a setting with limited resources. A preplanned substudy of MOTIVATE-ICU will explore timing, complications and outcomes in patients undergoing tracheostomy in a low income country like Uganda, complementing data from LMICs from other African countries45,46.
The strengths of the current study are its prospective design, registry-embedded nature, and multicenter inclusion. There are several potential limitations of this study. For example, while efforts are made to ensure data quality and reduce missing data, the reliance on electronic data collection and the prospective nature of the study may still encounter challenges with data completeness and accuracy across multiple centers. The study's findings, especially those related to organizational structure and process-related factors, may be specific to the context of low-income countries and thus may not be generalizable to settings with different healthcare systems, resources, and ICU capabilities. The cross-sectional survey assessing the organizational structure of ICUs, rely on self-reported data, which can introduce biases and inaccuracies.
Acknowledgements:
We thank all the site leads and data entrants of each site at each of the participating hospitals as well as Critical Care Asia Africa network for the support and involvement in the success of this study.
Funding:
The study will be supported by the Wellcome award, Collaboration for Research, Implementation and Training in Critical Care in Asia and Africa (Grant number: 224048/Z/21/Z).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 28 Days
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients ≥15 years receiving invasive mechanical ventilation within the ICU
Key inclusion criteria (1 listed)
- Invasive mechanical ventilatory support initiated anywhere within the study hospital i.e., emergency room, normal ward or in the operating room, or in the ICU at any time during admission.
Key exclusion criteria (4 listed)
- Successful extubations within two calendar days of intubation
- Admissions for end-of-life care and/or ICU palliative support
- Patients transferred from ICUs not participating in the study 24 hours after initiation of MV.
- Refusal or Withdrawal of consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ICU mortality
Time frame: 28 days
Death at ICU discharge, or at 28 days after ICU admission, whichever occurs first.
ICU Length of Stay
Time frame: 28 days
Number of days patients spend in the ICU. Measured per episode of ICU care. Calculated using the interval (measured in hours) between the date and time of ICU admission and the date and time of ICU discharge. Rounded to the nearest 1 decimal place.
Duration of mechanical ventilation
Time frame: 28 days
The time between endotracheal intubation and successful extubation (in case of intermittent mechanical ventilation via a tracheostomy, every day a patient needs ventilation counts as one extra day, irrespective of the duration of ventilation on that specific day). In case of non-invasive ventilation, the duration will be assessed separated from the assessment of invasive ventilation.
9 secondary outcomes
Duration of non-pulmonary organ support
Time frame: 28 days
ICU-Free days
Time frame: 28 days
Ventilator-free days
Time frame: 28 days
Ventilator-associated Pneumonia
Time frame: 28 days
Tracheobronchitis
Time frame: 28 days
Non-infectious Pulmonary complication
Time frame: 28 days
Readmission
Time frame: 28 days
Unplanned extubations
Time frame: 28 days
Tracheostomy related outcomes
Time frame: 28 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2024.
- Background: PubMed 27757516Laffey JG, Bellani G, Pham T, Fan E, Madotto F, Bajwa EK, Brochard L, Clarkson K, Esteban A, Gattinoni L, van Haren F, Heunks LM, Kurahashi K, Laake JH, Larsson A, McAuley DF, McNamee L, Nin N, Qiu H, Ranieri M, Rubenfeld GD, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators and the ESICM Trials Group. Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. Intensive Care Med. 2016 Dec;42(12):1865-1876. doi: 10.1007/s00134-016-4571-5. Epub 2016 Oct 18.
- Background: PubMed 27230398Prin M, Itaye T, Clark S, Fernando RJ, Namboya F, Pollach G, Mkandawire N, Sobol J. Critical Care in a Tertiary Hospital in Malawi. World J Surg. 2016 Nov;40(11):2635-2642. doi: 10.1007/s00268-016-3578-y.
- Background: PubMed 20934212Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010 Oct 16;376(9749):1339-46. doi: 10.1016/S0140-6736(10)60446-1. Epub 2010 Oct 11.
- Background: PubMed 27203509Goligher EC, Ferguson ND, Brochard LJ. Clinical challenges in mechanical ventilation. Lancet. 2016 Apr 30;387(10030):1856-66. doi: 10.1016/S0140-6736(16)30176-3. Epub 2016 Apr 28.
- Background: PubMed 30531535Inglis R, Ayebale E, Schultz MJ. Optimizing respiratory management in resource-limited settings. Curr Opin Crit Care. 2019 Feb;25(1):45-53. doi: 10.1097/MCC.0000000000000568.
- Background: PubMed 26903337Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291.
- Background: PubMed 27717861Neto AS, Barbas CSV, Simonis FD, Artigas-Raventos A, Canet J, Determann RM, Anstey J, Hedenstierna G, Hemmes SNT, Hermans G, Hiesmayr M, Hollmann MW, Jaber S, Martin-Loeches I, Mills GH, Pearse RM, Putensen C, Schmid W, Severgnini P, Smith R, Treschan TA, Tschernko EM, Melo MFV, Wrigge H, de Abreu MG, Pelosi P, Schultz MJ; PRoVENT; PROVE Network investigators. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med. 2016 Nov;4(11):882-893. doi: 10.1016/S2213-2600(16)30305-8. Epub 2016 Oct 4.
- Background: PubMed 29619334Khatib KI, Dixit SB, Joshi MM. Factors determining outcomes in adult patient undergoing mechanical ventilation: A "real-world" retrospective study in an Indian Intensive Care Unit. Int J Crit Illn Inj Sci. 2018 Jan-Mar;8(1):9-16. doi: 10.4103/IJCIIS.IJCIIS_41_17.
- Background: PubMed 28624388Laffey JG, Madotto F, Bellani G, Pham T, Fan E, Brochard L, Amin P, Arabi Y, Bajwa EK, Bruhn A, Cerny V, Clarkson K, Heunks L, Kurahashi K, Laake JH, Lorente JA, McNamee L, Nin N, Palo JE, Piquilloud L, Qiu H, Jimenez JIS, Esteban A, McAuley DF, van Haren F, Ranieri M, Rubenfeld G, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study. Lancet Respir Med. 2017 Aug;5(8):627-638. doi: 10.1016/S2213-2600(17)30213-8. Epub 2017 Jun 15.
- Background: PubMed 34022988African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet. 2021 May 22;397(10288):1885-1894. doi: 10.1016/S0140-6736(21)00441-4.
- Background: PubMed 29564726Simonis FD, Barbas CSV, Artigas-Raventos A, Canet J, Determann RM, Anstey J, Hedenstierna G, Hemmes SNT, Hermans G, Hiesmayr M, Hollmann MW, Jaber S, Martin-Loeches I, Mills GH, Pearse RM, Putensen C, Schmid W, Severgnini P, Smith R, Treschan TA, Tschernko EM, Vidal Melo MF, Wrigge H, de Abreu MG, Pelosi P, Schultz MJ, Neto AS; PRoVENT investigators; PROVE Network investigators. Potentially modifiable respiratory variables contributing to outcome in ICU patients without ARDS: a secondary analysis of PRoVENT. Ann Intensive Care. 2018 Mar 21;8(1):39. doi: 10.1186/s13613-018-0385-7.
- Background: PubMed 26262995Karthikeyan B, Kadhiravan T, Deepanjali S, Swaminathan RP. Case-Mix, Care Processes, and Outcomes in Medically-Ill Patients Receiving Mechanical Ventilation in a Low-Resource Setting from Southern India: A Prospective Clinical Case Series. PLoS One. 2015 Aug 11;10(8):e0135336. doi: 10.1371/journal.pone.0135336. eCollection 2015.
- Individual participant dataSharing planned: No
Related trials for Critical Illness
RecruitingPhase 4
Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Acute Kidney Injury
Not yet recruiting
Building Resilience Through Anxiety Virtual Education in PICU Survivors
Critical Illness Recovery, Mental Health
Active, not recruiting
PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children
Critical Illness
RecruitingPhase 3
A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
Septic Shock
Not yet recruiting
Feasibility Study on the Use of a Walking Exoskeleton in the Intensive Care Unit
Neuromuscular Disease in Post-Intensive Care Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Illness and Invasive Mechanical Ventilation, run by Nat Intensive Care Surveillance - MORU.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Cornelius Sendagire, M.Med (+256709624367, cornelius.sendagire@mak.ac.ug), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ICU mortality (time frame: 28 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06288724, which also lists 51 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2024.